Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Collaboration › Details

Exscientia–Rallybio: orphan drug discovery, 201907– collab €na joint venture to discover small molecule drugs using Centaur Chemist platform

 

Period Period 2019-07-23
Organisations Partner, 1st RE Ventures (joint venture of Rallybio + Exscientia)
  Group Exscientia (Group)
  Partner, 2nd Rallybio LLC
Products Product drug discovery
  Product 2 Centaur Chemist™ AI-based drug discovery platform
     

Exscientia Ltd.. (7/23/19). "Press Release: Exscientia Enters Broad Rare Disease Drug Discovery Collaboration with Rallybio".

Joint venture will initiate drug discovery programs targeting rare diseases using AI


Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered into a collaboration with Rallybio, a U.S.-based drug development company, which aims to transform lives of patients with rare diseases. The collaboration will combine Exscientia’s AI drug discovery platform with Rallybio’s expertise in rare disease drug development to accelerate the discovery of small molecule drug therapeutics for undisclosed rare disease indications.

It is estimated that there are between 7,000 and 8,000 rare diseases, which affect 25 to 30 million Americans and 30 to 40 million European Union citizens. These diseases pose unique challenges to the healthcare systems around the world because they require specific medical expertise and significant drug research, diagnostic and screening capabilities in order to treat these patients.

Alongside the team of world-class scientists from Rallybio, Exscientia will apply its cutting-edge, Centaur Chemist™, AI drug discovery platform to design pre-clinical drug candidates for the joint venture, RE Ventures, owned equally by Exscientia and Rallybio. The financial details of the collaboration are not disclosed.

“There is a huge potential for artificial intelligence to revolutionise and democratise rare disease drug discovery. AI can fast track, simplify and lower the price of research and we are thrilled to be partnering with Rallybio to achieve this. The future of drug discovery in rare diseases is to be able to address the need for precision engineered drugs at scale and our collaboration with Rallybio is the first step in this direction,” said Andrew Hopkins, CEO of Exscientia.

“Our joint venture brings together Exscientia’s industry-leading AI drug discovery capabilities with Rallybio’s expertise in rare disease drug development,” said Steve Uden, Chief Operating Officer of Rallybio. “We believe this collaboration will accelerate the development of life-transforming therapies for patients suffering from severe and rare disorders.”


About Exscientia

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.

Exscientia’s innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.

Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria.

As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.

Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including GSK, Sanofi and Evotec.

Exscientia has its headquarters in Oxford, UK, with offices in the UK, USA and Japan. For more information visit www.exscientia.co.uk or follow us on Twitter @exscientialtd


Media enquiries:

Edelman PR

Sesh Rahim +44(0) 203 0474207
Camille Oster +44(0) 7812660934
exscientia@edelman.com

Corporate enquiries:

Mark Swindells - Chief Operating Officer
contact@exscientia.co.uk

   
Record changed: 2019-09-03

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Exscientia (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top